|

PA9159 Metered-Dose Inhaler, 240 μg per day for 28 days Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Anhui Palo Alto Pharmaceuticals, Inc.1

Indications

  • Bronchial Asthma1
  • Asthma1

Other1 trial

Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.